GWM
LYRA

Geneos Wealth Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Geneos Wealth Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71
Closed -$920 – 2931
2024
Q3 		$920 Buy
+71
New +$1.04K ﹤0.01% 2464

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geneos Wealth Management's LYRA Position: Q4 2024 in Review

Geneos Wealth Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2024, closing a stake of 71 shares — an estimated $920 sold.

Geneos Wealth Management first reported a position in LYRA in Q3 2024 and held it in 1 quarter. The position peaked at $920 in Q3 2024. 54 funds tracked by Wall St. Rank hold LYRA as of Q4 2024.

  • Geneos Wealth Management reported no remaining LYRA THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
  • Geneos Wealth Management sold 71 LYRA THERAPEUTICS INC shares in Q4 2024, an estimated $920.
  • Geneos Wealth Management first reported a position in LYRA THERAPEUTICS INC in Q3 2024 and held it in 1 quarter.
  • Geneos Wealth Management's LYRA THERAPEUTICS INC position peaked at $920 in Q3 2024.
  • 54 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2024.

Based on Geneos Wealth Management's 13F filing for Q4 2024, filed 21 Jan 2025.